MannKind Corp (MNKD) stock
MNKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30119% above fair value
$3.95−0.12 (-2.95%)
Close on Nov 19, 2026Market cap $1.27BP/E –Yield –
MannKind free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
MannKind's free cash flow for the twelve months ending Jun 30, 2026 was -$18.14M, down 163.0% year over year. For fiscal 2025 it was $13.69M, down 58.3% from the year before. The highest annual figure on record is $32.82M in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.69M | -58.3% |
| FY2024 | Dec 31, 2024 | $32.82M | – |
| FY2023 | Dec 31, 2023 | -$8.35M | – |
| FY2022 | Dec 31, 2022 | -$88.27M | – |
| FY2021 | Dec 31, 2021 | -$73.18M | – |
| FY2020 | Dec 31, 2020 | -$28.93M | – |
| FY2019 | Dec 31, 2019 | -$91.05M | – |
| FY2018 | Dec 31, 2018 | -$38.09M | – |
| FY2016 | Dec 31, 2016 | -$79.23M | – |
| FY2015 | Dec 31, 2015 | -$67.52M | – |
| FY2014 | Dec 31, 2014 | -$20.01M | – |
| FY2013 | Dec 31, 2013 | -$136.72M | – |
| FY2012 | Dec 31, 2012 | -$120.50M | – |
| FY2011 | Dec 31, 2011 | -$130.70M | – |
| FY2010 | Dec 31, 2010 | -$158.20M | – |
| FY2009 | Dec 31, 2009 | -$202.94M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$23.45M | -399.4% |
| Q1 FY2026 | Mar 31, 2026 | -$7.25M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.95M | -150.4% |
| Q3 FY2025 | Sep 30, 2025 | $22.52M | +184.5% |
| Q2 FY2025 | Jun 30, 2025 | $7.83M | +809.8% |
| Q1 FY2025 | Mar 31, 2025 | -$6.71M | -256.2% |
| Q4 FY2024 | Dec 31, 2024 | $19.75M | +25.0% |
| Q3 FY2024 | Sep 30, 2024 | $7.91M | – |
| Q2 FY2024 | Jun 30, 2024 | $861.00K | – |
| Q1 FY2024 | Mar 31, 2024 | $4.30M | – |
| Q4 FY2023 | Dec 31, 2023 | $15.80M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.72M | – |
| Q2 FY2023 | Jun 30, 2023 | -$14.27M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.16M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.47M | – |
| Q3 FY2022 | Sep 30, 2022 | -$28.34M | – |
| Q2 FY2022 | Jun 30, 2022 | -$29.15M | – |
| Q1 FY2022 | Mar 31, 2022 | -$23.30M | – |
| Q4 FY2021 | Dec 31, 2021 | -$17.54M | – |
| Q3 FY2021 | Sep 30, 2021 | -$19.43M | – |
| Q2 FY2021 | Jun 30, 2021 | -$22.50M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.71M | – |
| Q4 FY2020 | Dec 31, 2020 | -$262.00K | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.46M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.83M | – |
| Q1 FY2020 | Mar 31, 2020 | -$11.37M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.22M | – |
| Q3 FY2019 | Sep 30, 2019 | -$53.01M | – |
| Q2 FY2019 | Jun 30, 2019 | -$20.95M | – |
| Q1 FY2019 | Mar 31, 2019 | -$11.87M | – |
| Q4 FY2016 | Dec 31, 2016 | -$12.75M | – |
| Q3 FY2016 | Sep 30, 2016 | -$23.07M | – |
See a number that looks wrong?